ATE340587T1 - Stabilisierte wachstumshormon zubereitung und verfahren zu deren herstellung - Google Patents

Stabilisierte wachstumshormon zubereitung und verfahren zu deren herstellung

Info

Publication number
ATE340587T1
ATE340587T1 AT97902109T AT97902109T ATE340587T1 AT E340587 T1 ATE340587 T1 AT E340587T1 AT 97902109 T AT97902109 T AT 97902109T AT 97902109 T AT97902109 T AT 97902109T AT E340587 T1 ATE340587 T1 AT E340587T1
Authority
AT
Austria
Prior art keywords
growth hormone
buffer
stabilizing agent
production
hormone preparation
Prior art date
Application number
AT97902109T
Other languages
German (de)
English (en)
Inventor
Michael Kevin Mcnamara
William Neil Charman
Susan Ann Charman
Original Assignee
Csl Ltd
Univ Monash
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3792327&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE340587(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Csl Ltd, Univ Monash filed Critical Csl Ltd
Application granted granted Critical
Publication of ATE340587T1 publication Critical patent/ATE340587T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT97902109T 1996-02-12 1997-02-12 Stabilisierte wachstumshormon zubereitung und verfahren zu deren herstellung ATE340587T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPN8012A AUPN801296A0 (en) 1996-02-12 1996-02-12 Stabilised growth hormone formulation and method of preparation thereof

Publications (1)

Publication Number Publication Date
ATE340587T1 true ATE340587T1 (de) 2006-10-15

Family

ID=3792327

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97902109T ATE340587T1 (de) 1996-02-12 1997-02-12 Stabilisierte wachstumshormon zubereitung und verfahren zu deren herstellung

Country Status (12)

Country Link
US (1) US6593296B1 (https=)
EP (1) EP0889733B1 (https=)
JP (1) JP4255515B2 (https=)
CN (1) CN1132626C (https=)
AT (1) ATE340587T1 (https=)
AU (1) AUPN801296A0 (https=)
CA (1) CA2246501C (https=)
DE (1) DE69736739T2 (https=)
DK (1) DK0889733T3 (https=)
RU (1) RU2191029C2 (https=)
TR (1) TR199801558T2 (https=)
WO (1) WO1997029767A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277410B1 (en) * 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
ES2300268T3 (es) * 1999-07-12 2008-06-16 Sandoz Ag Formulaciones de las hormonas de crecimiento.
AT408721B (de) * 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
AU2001238540A1 (en) 2000-02-24 2001-09-03 Monsanto Technology Llc Non-aqueous injectable formulations for extended release of somatotropin
AU2001271491A1 (en) 2000-06-26 2002-01-08 Monsanto Technology Llc Non-aqueous surfactant-containing formulations for extended release of somatotropin
US6664234B1 (en) 2000-06-30 2003-12-16 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
GB2371227A (en) * 2001-01-10 2002-07-24 Grandis Biotech Gmbh Crystallisation - resistant aqueous growth hormone formulations
JP4610154B2 (ja) * 2002-05-30 2011-01-12 大塚製薬株式会社 注射用製剤
CN1744914A (zh) * 2002-12-31 2006-03-08 阿尔特斯制药公司 人生长激素晶体和制备它们的方法
JP4949828B2 (ja) * 2003-03-18 2012-06-13 アレス トレーディング ソシエテ アノニム 溶液中での成長ホルモンの安定化
JP2007506683A (ja) * 2003-09-25 2007-03-22 カンジェーン コーポレイション ヒト成長ホルモン剤およびその調整方法と使用方法
US8338374B2 (en) * 2003-12-23 2012-12-25 Pharmacia Corporation Stable growth hormone liquid formulation
US7662393B2 (en) 2004-04-07 2010-02-16 Ares Trading S.A. Liquid growth hormone formulation and method of use
AU2005303818B2 (en) 2004-11-09 2011-06-23 Ares Trading S.A. Method for purifying FSH
SG155183A1 (en) 2005-08-26 2009-09-30 Ares Trading Sa Process for the preparation of glycosylated interferon beta
EP1960419B1 (en) 2005-12-09 2016-03-16 Ares Trading S.A. Method for purifying fsh or a fsh mutant
CN105412910A (zh) * 2006-07-06 2016-03-23 株式会社大熊 稳定的人生长激素液体制剂
EP2049148B1 (en) * 2006-07-06 2016-09-28 Daewoong Co., Ltd. A stable liquid formulation of human growth hormone
JP6244079B2 (ja) 2008-04-21 2017-12-06 ノボ ノルディスク ヘルス ケア アーゲー 乾燥トランスグルタミナーゼ組成物
JP6363949B2 (ja) * 2011-07-25 2018-07-25 サンド アクチェンゲゼルシャフト 少なくとも中性塩および生物薬学的タンパク質を含む、水性製剤
US10064951B2 (en) * 2012-03-30 2018-09-04 Hanmi Science Co., Ltd. Liquid formulation of highly concentrated long-acting human growth hormone conjugate
TW201605468A (zh) * 2013-09-27 2016-02-16 韓美藥品股份有限公司 長效人類生長激素接合物之製劑

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB131864A (https=)
DE3325223A1 (de) * 1983-07-13 1985-01-24 Hoechst Ag, 6230 Frankfurt Gegen denaturierung bestaendige, waessrige proteinloesungen, verfahren zu ihrer herstellung und ihre verwendung
JPS6270319A (ja) * 1985-07-30 1987-03-31 インタ−ナシヨナル・ミネラルズ・アンド・ケミカル・コ−ポレイシヨン 成長促進ホルモンの安定化
IT1222395B (it) * 1987-07-30 1990-09-05 Pierrel Spa Composizione farmaceutica per somministrazione intranasale comprendente l'ormone ghrh,un agonista colinergico e/o un sale biliare
EP0303746B2 (en) 1987-08-21 1998-12-02 Mallinckrodt Group Inc. Stabilization of growth promoting hormones
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
GB8822857D0 (en) * 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
EP0374120A3 (en) * 1988-12-13 1991-07-31 Monsanto Company Comosition for controlled release of polypeptides
US5013714A (en) * 1988-12-15 1991-05-07 Lindstrom Richard L Viscoelastic solution
US4994439A (en) * 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
US5182258A (en) 1989-03-20 1993-01-26 Orbon Corporation Systemic delivery of polypeptides through the eye
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5210017A (en) * 1990-11-19 1993-05-11 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
SE9201073D0 (sv) 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
ES2153385T5 (es) * 1992-07-31 2008-09-01 Genentech, Inc. Composicion acuosa a base de hormona del crecimiento humana.
DE69329795T2 (de) * 1992-10-02 2001-07-05 Genetics Institute, Inc. Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
DE69426292T2 (de) * 1993-02-23 2001-05-17 Genentech, Inc. Stabilisierung von mit organischen lösungsmittel behandelten polypeptiden mit einem hilfsstoff
AU692506B2 (en) * 1993-11-17 1998-06-11 Ibah, Inc. Transparent liquid for encapsulated drug delivery

Also Published As

Publication number Publication date
CN1214633A (zh) 1999-04-21
EP0889733A4 (en) 1999-11-03
CA2246501A1 (en) 1997-08-21
US6593296B1 (en) 2003-07-15
WO1997029767A1 (en) 1997-08-21
EP0889733A1 (en) 1999-01-13
EP0889733B1 (en) 2006-09-27
CA2246501C (en) 2012-07-10
TR199801558T2 (xx) 1998-11-23
DE69736739T2 (de) 2007-08-16
DK0889733T3 (da) 2007-01-29
JP4255515B2 (ja) 2009-04-15
AUPN801296A0 (en) 1996-03-07
CN1132626C (zh) 2003-12-31
HK1017851A1 (en) 1999-12-03
RU2191029C2 (ru) 2002-10-20
DE69736739D1 (de) 2006-11-09
JP2000504696A (ja) 2000-04-18

Similar Documents

Publication Publication Date Title
ATE340587T1 (de) Stabilisierte wachstumshormon zubereitung und verfahren zu deren herstellung
BR9307700A (pt) Formulação para estabilizar uma composição enzimática lìquida, composição enzimática lìquida estabilizada, método para a preparação de uma composição enzimática lìquida estabilizada e método para estabilizar uma composição enzimática lìquida
HUP0301124A2 (hu) Elszíneződésre nem hajlamos. minoxidil-tartalmú kompozíció és eljárás minoxidiltartalmú kompozíció elszíneződésének megakadályozására
NO305281B1 (no) FremgangsmÕte for Õ lagringsstabilisere pereddiksyrel°sninger, samt stabiliserte pereddiksyrel°sninger
RU98117135A (ru) Композиция стабилизированного гормона роста и способ ее приготовления
ATE198149T1 (de) Verfahren zur stabilisierung von duocarmycinderivaten
DE69531314D1 (de) Verwendung von metallionen chelatoren zur stabilisierung von interferon-enthaltenden pharmazeutischen zubereitungen
ATE259656T1 (de) Immunoglobulin enthaltende zusammensetzung
GB9928820D0 (en) Stable high glycerol liquids comprising sulfosuccinic acid monoesters
KR900013964A (ko) 활성형 비타민 d₃류 제제용 조성물 및 이를 함유하는 안정한 활성형 비타민 d₃류 제제의 제조방법
US5538989A (en) Fenbendazole formulations
ATE203392T1 (de) Stabilisierte pseudoemulsionen und verfahren zu ihrer herstellung
CA2463681A1 (en) Ready-to-use paracetamol injection solutions containing propylene glycol as the only cosolvent
DK1073331T3 (da) Koncentratsammensætning af en plantebehandlingsforbindelse i syreform
EP0010437A2 (en) Stable erythromycin solution and process therefor
JP4189223B2 (ja) ミノキシジル配合液剤組成物
RU97107154A (ru) Водные композиции, содержащие ципрофлоксацин, их применение и способ получения
DE69501183D1 (de) Feste orale pharmazeutische Zubereitung mit Gemfibrozil als aktiver Inhaltsstoff und Verfahren zur Herstellung
KR880008810A (ko) [벤조-1,2,4-티아디아진]-1,1-디옥사이드 용해 조성물
DE69003297D1 (de) Strahlungssterilisierbare antimikrobielle Salbe sowie Verfahren zu deren Herstellung.
US4579960A (en) Stable solutions containing thimerosal
JPS5531028A (en) Injection
RU94032143A (ru) Композиция, содержащая препарат коагуляционного фактора viii, способ ее получения и применение поверхностно-активного вещества в качестве стабилизатора
EP0352510A3 (en) Process for preparing a silver halide emulsion
KR950016751A (ko) 퀴놀론 항균제의 신규 주사용 조성물 및 그 제조방법

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0889733

Country of ref document: EP